Have any questions? 706-721-6582 or cts@augusta.edu
- LAI116482: A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naive adult subjects
Clinical Trial
LAI116482: A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naive adult subjects
This study will see how safe, effective, and well tolerated 3 different doses of a new HIV medication are when used along with 2 other approved medications to treat HIV.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 or older who have never taken anti-HIV medication before 2. HIV viral load count at least 1000 and CD4 count at least 200 EXCLUSION: 1. Certain medical conditions not allowed by the study, and labs outside of ranges allowed by the study 2. Patient has received medications or treatments not allowed within specific timeframes by the study
RESEARCH. INNOVATION. DISCOVERY.